Compare Vanguard Information Technology Index Fund ETF (VGT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Information Technology Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Information Technology Index Fund ETF trades at $127.98 (market cap $170.20B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 5.6× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Information Technology Index Fund ETF for 129 Days and Zoetis Inc for 70 Days on average.
| VGT | ZTS | |
|---|---|---|
Market Cap | $170.20B | $30.20B |
Volume | 5,132,883 | 6,175,327 |
52-Week High | $129.79 | $147.53 |
52-Week Low | $83.59 | $69.09 |
Typical Hold Time | 129 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VGT trades at $127.98, down 1.07% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong historical performance and appeal for long-term growth, with a focus on technology sector exposure. The ETF's low expense ratio and concentration in top tech names like Nvidia, Apple, and Microsoft are key attractions.
Outlook remains positive given tech sector momentum, but risks include high concentration in a few stocks and sensitivity to AI growth trends. Dividend yield is minimal, emphasizing capital appreciation over income. Investors should weigh sector volatility against long-term growth potential.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
